financetom
Business
financetom
/
Business
/
Costamare's Q1 Adjusted Earnings, Voyage Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Costamare's Q1 Adjusted Earnings, Voyage Revenue Rises
May 10, 2024 4:06 AM

06:36 AM EDT, 05/10/2024 (MT Newswires) -- Costamare ( CMRE ) reported Q1 adjusted earnings Friday of $0.63 per share, up from $0.38 a year earlier.

Three analysts polled by Capital IQ expected $0.62.

Voyage revenue for the quarter ended March 31 was $470.2 million, up from $248.8 million a year earlier.

One analyst surveyed by Capital IQ expected $336.2 million.

Price: 13.52, Change: +0.09, Percent Change: +0.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
National Bank on Quebecor's Wireless Opportunity Outside of Quebec
National Bank on Quebecor's Wireless Opportunity Outside of Quebec
Jun 28, 2024
12:48 PM EDT, 06/28/2024 (MT Newswires) -- Some commentators have questioned Quebecor's ability to succeed outside Quebec, given aggressive moves by the Big 3 to smother Freedom pricing over the past 14 months, notes National Bank. Analyst Adam Shine estimates over 4.6 million wireless subscribers will churn in Ontario, Manitoba, Alberta, and British Columbia this year. While he acknowledges that...
What's Going On With Rivian Stock Friday?
What's Going On With Rivian Stock Friday?
Jun 28, 2024
Rivian Automotive, Inc. ( RIVN ) shares are trading lower Friday after the stock gained earlier in the week following the announcement of a partnership with Volkswagen and the company's investor day. The Details: Rivian held its investor day Thursday and said it expects second-quarter vehicle production to be in a range of 9,100 to 9,300 units with a total...
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India
Jun 28, 2024
12:46 PM EDT, 06/28/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) plans to co-market Zydus Lifesciences' Pertuzumab biosimilar to treat breast cancer patients in India. Zydus will market the product under the Sigrima brand name while Dr. Reddy's will sell it as Womab, the companies said Friday. Dr. Reddy's will make an undisclosed upfront payment for the license and make...
--GSK Reaches Confidential Settlement in Illinois Zantac Litigation
--GSK Reaches Confidential Settlement in Illinois Zantac Litigation
Jun 28, 2024
12:52 PM EDT, 06/28/2024 (MT Newswires) -- GSK (GSK) Price: 38.92, Change: +0.27, Percent Change: +0.71 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved